AKAP12 and ovarian serous adenocarcinoma: AIF1 has been demonstrated to reinforce the resistance of breast cancer cells to cisplatin by inhibition of cell apoptosis and reduction of intracellular cisplatin accumulation [26] and AKAP12 is associated with paclitaxel-resistance in serous ovarian cancer [25].